Lesley Portnoy

Food and Drug Administration

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altria Group, Inc. | Globe Newswire | 11/15/2019

… Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On December 20, 2018, Altria acquired a 35% stake in investment in JUUL Labs, Inc. (“JUUL”), the purported U.S. leader in electronic vapor products, including e-cigarettes. On April 3, 2019, the U.S. Food and Drug Administration (“FDA”) announced its investigation into nearly three dozen cases of people suffering …

Follow Lesley Portnoy:    

Henry Schein

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Covetrus, Inc. | Globe Newswire | 11/15/2019

November 29, Covetrus, Inc. (“Covetrus” or the “Company”) (NASDAQ: CVET ) investors who purchased common stock between February 8, 2019 and August 12, 2019, inclusive In February 2019, Covetrus was formed through a spin-off of Henry Schein’s Animal Health Business, which was merged with Vets First Choice (VFC). On August 13, 2019, before the market opened, Covetrus reported a net loss of $0.09 per share for the second quarter of …

Clinical Data

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | Globe Newswire | 11/8/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use of gammaCore, the Company’s treatment for pain associated with episodic …

electroCore

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | Globe Newswire | 11/8/2019

… the upcoming November 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR ) investors who acquired common stock pursuant and … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . In June 2018, electroCore

GeneSight

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 11/7/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested changes to the GeneSight test offering” after Myriad had provided the FDA with clinical evidence and other …

Myriad Genetics

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 11/7/2019

… Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN ) investors who purchased securities between September 2, 2016 and August 13, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Medicare

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ViewRay, Inc. | 11/5/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … had declined due in part to changes being made to Medicare reimbursement approaches first announced in November 2019 that could make purchases of new ViewRay systems less profitable for customers; (2) that the Company’s reported …

DXC Technology

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DXC Technology Company | Globe Newswire | 10/31/2019

… the upcoming November 15, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of DXC Technology Company (“DXC” or the “Company”) (NYSE: DXC ) investors who purchased common stock pursuant … participate. If you wish to learn more about this action, Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On February 6, 2019 …

Nektar Therapeutics

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics | Globe Newswire | 10/9/2019

Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR ) investors who purchased securities between February 15, 2019 and August 8, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire …

Evolent Health

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Evolent Health, Inc. (EVH) - GuruFocus.com | 10/4/2019

Evolent Health, Inc. (“Evolent” or the “Company”) (: EVH ) investors who purchased common stock between March 3, 2017 and May 28, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Abiomed

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Abiomed, Inc. | Globe Newswire | 10/3/2019

… Abiomed, Inc. (“Abiomed” or the “Company”) (NASDAQ: ABMD ) investors who purchased securities between January 31, 2019 and July 31, 2019, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire …

Curaleaf

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Curaleaf Holdings, Inc. | Benzinga | 9/26/2019

Curaleaf Holdings, Inc. (“Curaleaf” or the “Company”) (OTC: CURLF ) investors who purchased securities between November 21, 2018 and July 22, 2019, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Aclaris

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. | Globe Newswire | 9/25/2019

Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors who purchased securities between May 8, 2018 and June 20, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Aclaris Therapeutics

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. | Globe Newswire | 9/25/2019

Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors who purchased securities between May 8, 2018 and June 20, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Cardinal Health

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cardinal Health, Inc. | Globe Newswire | 9/24/2019

… the upcoming September 30, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Cardinal Health, Inc. (“Cardinal Health” or the “Company”) (NYSE: CAH ) investors who purchased common stock … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On August 2, 2017 …

Johnson & Johnson

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cardinal Health, Inc. | Globe Newswire | 9/24/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … Cordis”), which the Company had purchased in March 2015 from Johnson & Johnson (“J&J”). On this news, Cardinal Health’s share price fell $6.34 per share, or over 8%, to close at $70.99 on August 2 …

Oasmia Pharmaceutical

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB | Globe Newswire | 9/23/2019

Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) investors who purchased securities between October 23, 2015 and July 9, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Karyopharm Therapeutics

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. | Globe Newswire | 9/16/2019

… the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI ) investors that: (1) purchased shares of … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On February 22, 2019 …

Novartis

Glancy Prongay & Murray LLP Continues its Investigation on Behalf of Novartis AG Investors (NVS) | Benzinga | 9/12/2019

Novartis AG (“Novartis” or the “Company”) (NYSE: NVS ) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll …

Omnicell

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Omnicell, Inc. | Globe Newswire | 9/11/2019

Omnicell, Inc. (“Omnicell” or the “Company”) (NASDAQ: OMCL ) investors who purchased securities between October 25, 2018 and July 11, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire …